On the evening of April 2, Chinese beauty company Freda released its 2025 annual financial report.
According to the report, Freda recorded revenue of RMB 3.651 billion in 2025, representing a year-on-year decline of 8.33%, while net profit attributable to shareholders reached RMB 188 million, down 22.90% year-on-year.
It is understood that after divesting its real estate business, Freda’s core operations now cover cosmetics, pharmaceuticals, raw materials, and additives. During the reporting period, its cosmetics segment generated revenue of RMB 2.246 billion, down 9.27% year-on-year, with a gross margin of 62.55%, remaining largely flat compared to the same period last year.
Looking at brand performance, in 2025, Freda’s hyaluronic acid-focused moisturizing and repair brand Rellet saw its annual revenue exceed RMB 1 billion for the first time, growing 8.26% year-on-year to RMB 1.043 billion. Among its product lines, the spray category grew by 19% year-on-year, while the 2.0 series surged by 54%, maintaining the No.1 position in the facial mist category across major online platforms.
Meanwhile, the microbiome-based skincare brand Dr. Alva generated revenue of RMB 947 million, down 27.17% year-on-year. During the reporting period, channel adjustments began to take effect, with performance stabilizing and rebounding in the third quarter on a quarter-on-quarter basis, and further growth momentum expanding in the fourth quarter, indicating a steady recovery in sales.
In addition, the medical aesthetics brand Comy, which focuses on recombinant collagen, recorded revenue of RMB 155 million, representing a sharp year-on-year increase of 258%. Leveraging its patented transdermal collagen technology, the brand achieved over RMB 100 million in sales from its collagen ampoule products.
By channel, in 2025, Freda’s cosmetics revenue from online channels reached RMB 1.96 billion, down 8.96% year-on-year, while offline channel revenue was RMB 286 million, declining 11.39% year-on-year.
In 2025, Freda continued to strengthen its technological innovation capabilities, with R&D investment reaching RMB 183 million, accounting for 5.00% of total revenue. Its R&D team expanded to 442 employees, up 2.80% year-on-year. During the reporting period, the company filed 53 new patent applications and was granted 56 patents in the cosmetics segment, along with obtaining 85 domestic trademark registrations and 6 overseas trademark registrations.
